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Abstract
Background
Transcatheter aortic valve replacement (TAVR) has become a commonplace procedure
for the treatment of aortic stenosis in higher risk surgical patients. With the high cost and
steadily increasing number of patients receiving TAVR, emphasis has been placed on opti-
mizing outcomes as well as resource utilization. Recently, studies have demonstrated the
feasibility of conscious sedation in lieu of general anesthesia for TAVR. This study aimed to
investigate the clinical as well as cost outcomes associated with conscious sedation in com-
parison to general anesthesia in TAVR.
Methods
Records for all adult patients undergoing TAVR at our institution between August 2012 and
June 2016 were included using our institutional Society of Thoracic Surgeons (STS) and
American College of Cardiology (ACC) registries. Cost data was gathered using the BIOME
database. Patients were stratified into two groups according to whether they received gen-
eral anesthesia (GA) or conscious sedation (CS) during the procedure. No-replacement
propensity score matching was done using the validated STS predicted risk of mortality
(PROM) as a propensity score. Primary outcome measure with survival to discharge and
several secondary outcome measures were also included in analysis. According to our insti-
tution’s data reporting guidelines, all cost data is presented as a percentage of the general
anesthesia control group cost.
Results
Of the 231 patients initially identified, 225 (157 GA, 68 CS) were included for analysis. After
no-replacement propensity score matching, 196 patients (147 GA, 49 CS) remained. Over-
all mortality was 1.5% in the matched population with a trend towards lower mortality in the
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CS group. Conscious sedation was associated with significantly fewer ICU hours (30 vs 96
hours, p = <0.001) and total hospital days (4.9 vs 10.4, p<0.001). Additionally, there was a
28% decrease in direct cost (p<0.001) as well as significant decreases in all individual all
cost categories associated with the use of conscious sedation. There was no difference in
composite major adverse events between groups. These trends remained on all subsequent
subgroup analyses.
Conclusion
Conscious sedation is emerging as a safe and viable option for anesthesia in patients under-
going transcatheter aortic valve replacement. The use of conscious sedation was not only
associated with similar rates of adverse events, but also shortened ICU and overall hospital
stays. Finally, there were significant decreases in all cost categories when compared to a
propensity matched cohort receiving general anesthesia.
Introduction
Aortic stenosis (AS) is a frequently encountered disease affecting 2–4% of the population over 75
years of age [1]. In recent years, transcatheter aortic valve replacement (TAVR) has steadily grown
in popularity as an alternative to traditional surgical intervention for patients with severe AS [2].
While Smith et al [3] showed superiority of TAVR to medical therapy in inoperable patients, it
has been demonstrated that TAVR has comparable outcomes to surgical aortic valve replacement
(SAVR) in patients with both high and intermediate operative risk (Society of Thoracic Surgeons
risk score) [4, 5]. With these expanded indications, application of TAVR is expected to increase in
the near future.
Despite its clinical efficacy, a number of investigators have reported TAVR to have consid-
erably higher costs when compared to SAVR. Notably, Reynolds et al showed significantly
higher cumulative 1-year costs among TAVR patients than patients who received surgical
intervention at approximately $60,000/year of life earned [6]. The high resource utilization
observed in TAVR may be in part due to the cost of the prosthesis and the prolonged period of
recovery from general anesthesia in elderly and frail patients.
Given the success and safety of conscious sedation (CS) in other surgical and interventional
procedures [7,8], this anesthetic technique has been recently applied to TAVR. Indeed, TAVR
using CS has been associated with less hemodynamic instability and catecholamine use, as well
as decreased respiratory and infectious complications [8,9]. The present study was performed to
systemically assess the clinical and financial outcomes associated with CS approach to TAVR at
our institution.
Methods
All adult patients undergoing isolated TAVR procedures for symptomatic severe aortic ste-
nosis between August 2012 and June 2016 were identified using our institutional Society of
Thoracic Surgeons (STS) database and American College of Cardiology (ACC) Transcath-
eter Valve Therapy Registry (TVTR). Patients were excluded for missing records, aborted
procedures, or significant outliers of cost as described below. Patients were stratified into
the general anesthesia (GA) group or conscious sedation (CS) group based on the type of
anesthesia delivered at initiation of the procedure. The decision of CS or GA was made on
Conscious sedation vs general anesthesia in TAVR
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an individual basis by the treatment team consisting of cardiologists, cardiac surgeons and
an anesthesiologist.
First-generation Sapien valves (Edwards Lifesciences, Irvine, CA) were initially used in all
cases and supplanted gradually in favor of Sapien XT in July 2014, and then by Sapien 3 in July
2015. All patients preferentially underwent transfemoral approach when deemed feasible by
preprocedural imaging, otherwise a transapical approach was used, requiring general
anesthesia.
Predicted Risk of Mortality (STS PROM) was calculated prior to the procedure by the treat-
ment team using the publicly available STS Risk Calculator. Missing values were supplemented
from electronic medical records when necessary and available.
All cost data was collected using our institution’s BIOME Database (BIOME Analytics, Sau-
salito, CA), a system that is able to merge hospital financial and clinical data. The primary out-
come of the study was in-hospital mortality, while secondary outcomes included hospital and
ICU lengths of stay, hospital costs, and adverse events. Given the relatively low incidence of
major adverse events (MAE’s), a composite variable was developed for analysis consisting of
the following MAE’s: all-cause mortality, myocardial infarction (MI), cardiac arrest, new pace-
maker requirement, new onset atrial fibrillation, major vascular event, ischemic stroke or TIA,
new need for dialysis, gastrointestinal and urinary bleeding(GI/GU), or other bleeding event,
annular disruption, hematoma or bleeding at access site, and unplanned or emergent cardiac
or vascular surgery. Quality of life as assessed using the validated Kansas City Cardiomyopathy
12-question survey (KCCQ12) [10], was also included as a secondary outcome.
Conscious sedation was defined as “a drug induced depression of consciousness during
which patients respond purposefully to verbal commands, either alone or accompanied by
light tactile stimulation. No intervention is required to maintain a patent airway, and sponta-
neous vent is adequate.” General anesthesia was defined as “drug-induced loss of conscious-
ness during which patients are not arousable, even by painful stimulation. The ability to
independently maintain ventilator function is often impaired. Patients often require assistance
in maintaining a patent airway, and positive pressure ventilation may be required because of
depressed spontaneous ventilation or drug-induced depression of neuromuscular function.”
[11]
Propensity score matching was used to control for significant intergroup differences and
account for potential selection biases. The STS predicted risk of mortality score, a previously
validated composite risk stratification, was used as our propensity score [12] (Table 1). All
patients without a match were then dropped and all subsequent analyses were completed on
the matched cohort.
Several distinct analyses were done with different levels of exclusions as illustrated in Fig 1.
Firstly, all patients undergoing isolated TAVR procedures with all valve and access choices
were analyzed. For the second analysis, all patients with a Sapien 1 (old generation device)
were excluded. In the final subanalysis, only patients with newer generation valves (Sapien XT
or Sapien 3) and who underwent a transfemoral approach were included in this analysis. The
cohorts were propensity matched again after each set of exclusions to assure completeness.
(Fig 1).
Continuous values are expressed as the mean and standard deviation and categorical vari-
ables as a number and percentage of group. Welch’s t-test of unequal variance and χ2- test
were used for analysis between groups when appropriate. An alpha of<0.05 was considered
statistically significant.
According to institutional policy, actual costs cannot be published. Instead, all cost data is
expressed as a percentage of the control (GA group) with a standard deviation. Additionally,
cost data used reflects only direct costs, all indirect costs have been omitted.
Conscious sedation vs general anesthesia in TAVR
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All statistical analyses were achieved using 13.0 (StataCorp, College Station, TX, USA). This
study was approved by the Institutional Review Board at the University of California, Los
Angeles.
Results
Patient and procedural characteristics
Of the 231 patients identified, 225 (157 GA, 68 CS) met inclusion criteria and underwent fur-
ther analysis. Five patients were excluded for aborted procedures and one for undergoing a
transaortic approach. After no-replacement propensity score matching a total of 196 matched
patients (147 GA, 49 CS) remained.
Table 1. Patient Characteristics, all matched patients.
Clinical Variable Total, n = 196 General, n = 147 Sedation, n = 49 P-value
Age, mean (SD), years 82.7 ± 11 82.4 ± 11 83.5 ± 9 0.45
Male, No. (%) 97 (49.5) 74 (50.3) 23 (46.9) 0.68
BMI, mean (SD), kg/m2 26.9 ± 6 26.8 ± 6 27.3 ± 5 0.59
NYHA class, No. (%) 0.09
Class 1 19 (9.7) 15 (10.2) 4 (8.2)
Class 2 72 (36.7) 56 (38.1) 16 (32.7)
Class 3 87 (44.4) 59 (40.1) 28 (57.1)
Class 4 18 (9.2) 17 (11.6) 1 (2)
STS Risk, Mort % (SD) 7.5 ± 4 7.6 ± 4 7.2 ± 6 0.65
Hypertension, No. (%) 155 (79.1) 117 (79.6) 38 (77.6) 0.77
Afib/Aflutter, No. (%) 68 (34.7) 53 (36.1) 15 (30.6) 0.48
Diabetes mellitus, No. (%) 65 (33.2) 54 (36.7) 11 (22.5) 0.051
Prior MI, No. (%) 70 (35.7) 56 (38.1) 14 (28.6) 0.22
PAD, No (%) 31 (15.8) 24 (16.3) 7 (14.3) 0.73
Hemoglobin, mean% (SD) 11.7 ± 2.2 11.4 ± 2.2 12.3 ± 12.1 0.02
Renal Status, No. (%) 0.68
Normal (Cr<2.0) 174 (88.8) 131 (89.1) 43 (87.8)
Insufficiency (Cr2, not on dialysis) 14 (7.1) 11 (7.5) 3 (6.1)
Failure (dialysis) 8 (4.1) 5 (3.4) 3 (6.1)
Hx stroke or TIA, No. (%) 31 = 3 (16.8) 25 (17.0) 8 (16.3) 0.91
LVEF, mean (SD) 53.6 ± 16 52.9 ± 16 56.7 ± 14 0.24
KCCQ Score 47.4 ± 26 46.6 ± 25 49.6 ± 27 0.50
Approach, No. (%) <0.001*
Transfemoral 132 (67.4) 83 (56.5) 49 (100)
Transapical 64 (32.7) 64 (43.5) 0 (0)
Valve Type, No. (%) <0.001*
Sapien 57 (29.1) 57 (38.8) 0 (0)
Sapien XT 65 (33.2) 65 (44.2) 0 (0)
Sapien 3 74 (37.8) 25 (17.0) 49 (100)
BMI, body-mass-index; NYHA, New York Heart Association; STS, Society of Thoracic Surgeons; Mort, mortality risk; Afib/Aflutter, atrial fibrillation or atrial
flutter; MI, myocardial infarction; PAD, peripheral vascular disease; TIA, transient ischemic attack; LVEF, left ventricular ejection fraction; KCCQ, Kansas
City Cardiomyopathy Questionnaire.
* = statistically significant
https://doi.org/10.1371/journal.pone.0173777.t001
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Pre-procedural characteristics were all similar between patient groups with the exception of
preoperative hemoglobin (Table 1). Only 1 case was converted from conscious sedation to
general anesthesia. Operative characteristic differences between groups persisted after propen-
sity score matching (Table 1) and, as a result, several subsequent subgroup analyses were per-
formed (as detailed below) (Fig 1).
Clinical outcomes
The overall in-hospital mortality was 1.5% for the matched population with a trend towards a
lower mortality in the CS group (0% CS vs 2% GA, p = 0.083). Overall, MAE’s occurred with
similar frequency in the two groups (33% CS vs 31% GA, p = 0.67); however, several individual
adverse events were statistically lower in the CS group (Table 2). When compared to GA,
patients in the CS group had significantly fewer ICU hours (30±31 vs 96±107, p =<0.001) and
hospital days (4.9±4 vs 10.4±9.5, p<0.001). At one-month follow-up, patients in the CS group
had significantly greater improvements in KCCQ12 quality of life scores when compared to
GA group (+40 ± 25 vs +29 ± 30, P = 0.025). 30-day readmission rates were no different
between groups (Table 2).
Cost outcomes
Cost data was available for all included patients. Costs for the CS group were significantly
lower in all categories (Table 3). Direct cost to the hospital for CS was 72% of what it was in
GA group (P = <0.001). All other cost categories were less than 50% of GA group.
Fig 1. Consort diagram. GA = General Anesthesia group. CS = Conscious Sedation group.
https://doi.org/10.1371/journal.pone.0173777.g001
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Subgroup analysis
Two subgroup analyses were performed as illustrated in Fig 1. The first excluded all Sapien 1
valves and the second excluded all Sapien 1 valves and all non-transfemoral procedures (Tables
Table 2. Clinical outcomes, all matched patients.
Outcomes Total, n = 196 General, n = 147 Sedation, n = 49 P-value
Mortality 3 (1.5%) 3 (2%) 0 (0%) 0.08
1+ Major Adverse Event 69 (35%) 53 (36%) 16 (33%) 0.67
MI 2 (1%) 2 (1.4%) 0 (0%) 0.16
Cardiac arrest 1 (0.5%) 1 (0.7%) 0 (0%) 0.32
Major Vasc Event 2 (1%) 1 (0.7%) 1 (2%) 0.53
Ischemic Stroke 3 (1.5%) 1(0.7%) 2 (4.1%) 0.25
TIA 1 (0.5%) 0 (0%) 1 (2%) 0.32
New Dialysis 7 (3.6%) 7 (4.8%) 0 (0%) 0.008*
GI Bleed 3 (1.5%) 3 (2%) 0 (0%) 0.08
GU Bleed 1 (0.5%) 1 (0.7%) 0 (0%) 0.32
Other Bleeding Event 6 (3.0%) 6 (4.1%) 0 (0%) 0.014*
Annular Dissection 1 (0.5%) 1 (0.7%) 0 (0%) 0.32
Hematoma @ site 3 (1.5%) 2 (1.4%) 1 (2%) 0.76
Bleeding @ site 7 (3.6%) 5(3.4%) 2 (4.1%) 0.83
Unplanned surgery 5 (2.6%) 5 (3.4%) 0 (0%) 0.024*
Req Pacemaker 26 (13%) 18 (12%) 8 (16%) 0.50
New onset Afib 20 (10%) 17 (12%) 3 (6.1%) 0.21
ICU Hours 76 ± 97 96 ± 107 30 ± 31 <0.001*
Length of Stay (days) 9.0 ± 8.8 10.4 ± 9.5 4.9 ± 4 <0.001*
30-day readmission 38 (19%) 30 (20%) 8 (16%) 0.52
LVEF @ 1 month** 58 ±12 58 ±13 59 ± 12 0.48
Change from preop +5 ± 11 +5 ±11 +3 ± 10 0.35
KCCQ @ 1 month 81 ± 21 78 ± 22 90 ± 11 <0.001*
Change from preop*** +32 ± 29 +29 ± 30 +40 ± 25 0.025*
MI, myocardial infarction; TIA, transient ischemic attack; GI, gastrointestinal; GU, genitourinary; Afib, atrial fibrillation; ICU, intensive care unit; LVEF, left
ventricular ejection fraction; KCCQ, Kansas City Cardiomyopathy Questionnaire
* = statistically significant
**LVEF 30 day available for total of 179 patients (135 GA, 44 CS)
***KCCQ 30 day available for total of 172 patients (129 GA, 43 CS)
https://doi.org/10.1371/journal.pone.0173777.t002
Table 3. Conscious sedation cost outcomes, all matched patients.
Cost Category % of GA Control Cost P-value
Total Direct Cost 71.5% <0.001*
ICU Direct Cost 45.3% <0.001*
Anesthesia Direct Cost 47.1% <0.001*
OR Recovery Direct Cost 42.6% <0.001*
Pharmacy Direct Cost 42.1% <0.001*
Room Direct Cost 45.5% <0.001*
ICU, intensive care unit; OR, operating room
* = statistically significant
https://doi.org/10.1371/journal.pone.0173777.t003
Conscious sedation vs general anesthesia in TAVR
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4 and 5). After exclusions of Sapien 1 valves, no in-hospital mortalities remained. In both sub-
analyses, ICU hours and total length of stay remained significantly less in the CS group (Tables
6 and 7). Additionally, all costs remained significantly lower in the CS group (Tables 8 and 9).
Discussion
Recent introduction of lower profile delivery systems and a wider range of valve sizes has
allowed more patients to receive TAVR through the transfemoral approach. During the natu-
ral evolution of TAVR technology, fast-track protocols and other procedural modifications
have been studied to reduce the cost of this procedure and improve clinical outcomes [8].
Nonetheless, the heavy resource utilization of TAVR technology remains a major concern.
In this study of TAVR patients with high operative risk, we found that the use of conscious
sedation was associated with improved hospital and ICU length of stay, improved quality of
life measures, and decreases in nearly every cost category. In our analysis of newer generation
Table 4. Patient characteristics; excluding Sapien 1 valves.
Clinical Variable Total, n = 139 General, n = 90 Sedation, n = 49 P-value
Age, mean (SD), years 82.1 ± 11 81.3 ± 12 83.5 ± 9 0.23
Male, No. (%) 72 (52) 46 (51) 26 (53) 0.83
BMI, mean (SD), kg/m2 27.5 ± 6 27.6 ± 7 27.3 ± 5 0.75
NYHA class, No. (%) 0.17
Class 1 14 (10.1) 10 (11.1) 4 (8.2)
Class 2 50 (36.0) 34 (37.8) 16 (32.6)
Class 3 65 (46.8) 37 (41.1) 28 (57.1)
Class 4 10 (7.2) 9 (10) 1 (2)
STS Risk, Mort % (SD) 7.2 ± 5 7.2 ± 4 7.2 ± 6 0.95
Hypertension, No. (%) 112 (80.6) 74 (82.2) 38 (77.6) 0.52
Afib/Aflutter, No. (%) 50 (36.0) 35 (38.9) 15 (30.6) 0.33
Diabetes mellitus, No. (%) 45 (32.3) 34 (37.8) 11 (22.4) 0.06
Prior MI, No. (%) 52 (37.4) 38 (42.2) 14 (28.6) 0.11
PAD, No (%) 19 (13.4) 12 (13.3) 7 (14.3) 0.89
Hemoglobin, mean% (SD) 11.8 ± 2.4 11.6 ± 2.4 12.3 ± 2.1 0.07
Renal Status, No. (%) 0.50
Normal (Cr<2.0) 125 (89.9) 82 (91.1) 43 (87.8)
Insufficiency (Cr2, not on dialysis) 9 (6.5) 6 (6.7) 3 (6.1)
Failure (dialysis) 5 (3.6) 2 (2.2) 3 (6.1)
Hx stroke or TIA, No. (%) 24 (17.3) 16 (17.8) 8 (16.3) 0.83
LVEF, mean (SD) 54.1 ± 16 53.2 ± 17 55.7 ± 14 0.35
KCCQ Score 49 ± 26 49 ± 26 50 ± 27 0.85
Approach, No. (%) <0.001*
Transfemoral 109 (78.4) 60 (66.7) 49 (100)
Transapical 30 (21.6) 30 (33.3) 0 (0)
Valve Type, No. (%) <0.001*
Sapien XT 65 (46.8) 65 (44.2) 0 (0)
Sapien 3 74 (53.2) 25 (17.0) 49 (100)
BMI, body-mass-index; NYHA, New York Heart Association; STS, Society of Thoracic Surgeons; Mort, mortality risk; Afib/Aflutter, atrial fibrillation or atrial
flutter; MI, myocardial infarction; PAD, peripheral vascular disease; TIA, transient ischemic attack; LVEF, left ventricular ejection fraction; KCCQ, Kansas
City Cardiomyopathy Questionnaire
* = statistically significant
https://doi.org/10.1371/journal.pone.0173777.t004
Conscious sedation vs general anesthesia in TAVR
PLOS ONE | https://doi.org/10.1371/journal.pone.0173777 April 5, 2017 7 / 12
TAVR prostheses deployed via the transfemoral approach, patients who received CS had at
least 30 fewer ICU hours and 4 fewer total hospital days as well as 25% reduced cost when
compared to GA.
Others have previously evaluated protocols for improving clinical outcomes in the frail
TAVR population. In a feasibility study, Jensen et al reported acceptable outcomes with a
“minimalist approach” to TAVR, a cornerstone of which was CS [13]. Similarly, Frohlich and
colleagues reported comparable clinical outcomes with CS when compared to GA [8]. Interest-
ingly, our study found improvements in clinical outcomes with CS among TAVR patients. It is
plausible that CS leads to less hemodynamic instability, and need for vasoactive agents which
may allow lower acuity care and “fast-tracking.” Additionally, less time in the hospital and
ICU hours in particular, has been independently shown to decrease risk of nosocomial infec-
tions and overall mortality [14].
Our reporting of cost outcomes associated with the institution of CS in the TAVR popula-
tion highlights several points. With an average 25% reduction in direct costs, reduced ICU and
room utilization accounted for the largest reductions with the introduction of CS. However,
operating room, pharmacy, and all directs costs were also lower with this method. We
Table 5. Patient characteristics; excluding Sapien 1 valves and transapical approach.
Clinical Variable Total, n = 109 General, n = 60 Sedation, n = 49 P-value
Age, mean (SD), years 81.8 ± 12 80.3 ± 14 83.5 ± 9 0.15
Male, No. (%) 53 (51%) 27 (45%) 26 (53%) 0.41
BMI, mean (SD), kg/m2 27.9 ± 7 28.5 ± 8 27.3 ± 5 0.33
NYHA class, No. (%) 0.23
Class 1 11 (10%) 7 (12%) 4 (8.2%)
Class 2 40 (37%) 24 (40%) 16 (33%)
Class 3 52 (48%) 24 (40%) 28 (57%)
Class 4 6 (5.5%) 5 (8.3%) 1 (2.0%)
STS Risk, Mort % (SD) 7.1 ± 6 7.0 ± 4 7.2 ± 6 0.79
Hypertension, No. (%) 84 (77%) 46 (77%) 38 (78%) 0.91
Afib/Aflutter, No. (%) 35 (32%) 20 (33%) 15 (31%) 0.76
Diabetes mellitus, No. (%) 35 (32%) 24 (40%) 11 (22%) 0.048*
Prior MI, No. (%) 38 (35%) 24 (40%) 14 (29%) 0.21
PAD, No (%) 9 (8.3%) 2 (3.3%) 7 (14%) 0.053
Hemoglobin, mean% (SD) 11.9 ± 2.4 11.6 ± 2.6 12.3 ± 2.1 0.12
Renal Status, No. (%) 0.79
Normal (Cr<2.0) 97 (89%) 54 (90%) 43 (88%)
Insufficiency (Cr2, not on dialysis) 7 (6.4%) 4 (6.7%) 3 (6.1%)
Failure (dialysis) 5 (4.6%) 2 (3.3%) 3 (6.1%)
Hx stroke or TIA, No. (%) 19 (17%) 11 (18%) 8 (16%) 0.79
LVEF, mean (SD) 54.7 ± 16 53.9 ± 17 55.6 ± 14 0.56
KCCQ Score 48.9 ± 26 48.2 ± 26 49.6 ± 27 0.79
Valve Type, No. (%) <0.001*
Sapien XT 43 (46.8%) 43 (72%) 0 (0%)
Sapien 3 66 (53.2%) 17 (28%) 49 (100%)
BMI, body-mass-index; NYHA, New York Heart Association; STS, Society of Thoracic Surgeons; Mort, mortality risk; Afib/Aflutter, atrial fibrillation or atrial
flutter; MI, myocardial infarction; PAD, peripheral vascular disease; TIA, transient ischemic attack; LVEF, left ventricular ejection fraction; KCCQ, Kansas
City Cardiomyopathy Questionnaire
* = statistically significant
https://doi.org/10.1371/journal.pone.0173777.t005
Conscious sedation vs general anesthesia in TAVR
PLOS ONE | https://doi.org/10.1371/journal.pone.0173777 April 5, 2017 8 / 12
performed several sublevel analyses controlling for the type of valve and delivery systems.
Even in the most restrictive analysis including only Sapien XT and Sapien 3 valves deployed
via the transfemoral approach, we found reductions in nearly all cost categories associated
with CS. With an average cost of $55K for TAVR reported by Babaliaros [15], this reduction in
costs would translate to nearly $14K per case. While institutional costs may vary significantly,
this study provides encouraging financial outcomes for administration of CS in TAVR
patients.
Finally, among the frail TAVR population, quality of life is an important consideration. We
used the validated KCCQ12 questionnaire to evaluate patient quality of life prior to their pro-
cedure and at their 30-day follow-up. Patients who underwent CS TAVR were found to have
higher quality of life scores at 30-days in two of three analyses. This may be explained by stress
(hemodynamic instability, increased postprocedural interventions, etc) on the body allowing
more robust response to treatment or possibly shorter hospital stays leading to more favorable
experiences with patients.
Table 6. Clinical outcomes, excluding Sapien 1 valves.
Outcomes Total, n = 139 General, n = 90 Sedation, n = 49 P-value
Mortality 0 (0%) 0 (0%) 0 (0%)
1+ Major Adverse Event 49 (35%) 33 (37%) 16 (33%) 0.64
MI 0 (0%) 0 (0%) 0 (0%) NA
Cardiac arrest 1 (1%) 1 (1%) 0 (0%) 0.32
Major Vasc Event 1 (1%) 0 (0%) 1 (2%) 0.32
Ischemic Stroke 3 (2%) 1(1%) 1 (4%) 0.34
TIA 1 (1%) 0 (0%) 1 (2%) 0.32
New Dialysis 3 (2%) 3 (3%) 0 (0%) 0.08
GI Bleed 1 (1%) 1 (1%) 0 (0%) 0.32
GU Bleed 0 (0%) 0 (0%) 0 (0%) NA
Other Bleeding Event 2 (1.4%) 2 (2%) 0 (0%) 0.16
Annular Dissection 1 (1%) 1 (1%) 0 (0%) 0.32
Hematoma @ site 2 (1.4%) 1 (1%) 1 (2%) 0.69
Bleeding @ site 6 (4.3%) 4 (4.4%) 2 (4.1%) 0.92
Unplanned surgery 2 (1.4%) 2 (2%) 0 (0%) 0.16
Req Pacemaker 24 (17.3%) 16 (17.8%) 8 (16.3%) 0.83
New onset afib 16 (11.5%) 13 (14.4%) 3 (6.1%) 0.10
ICU Hours 61 ± 67 78 ± 74 30 ± 31 <0.001*
Length of Stay (days) 8.1 ± 8.7 9.8 ± 10.1 4.9 ± 4.0 <0.001*
30-day readmission 26 (18.7%) 18 (20%) 8 (16.33%) 0.59
LVEF @ 1 month** 59 ±13 58 ±13 59 ± 12 0.74
Change from preop +5 ± 11 +5 ±11 +3 ± 10 0.33
KCCQ @ 1 month*** 83 ± 19 79 ± 22 90 ± 11 <0.001*
Change from preop +33 ± 28 +30 ± 29 +40 ± 25 0.037*
MI, myocardial infarction; TIA, transient ischemic attack; GI, gastrointestinal; GU, genitourinary; Afib, atrial fibrillation; ICU, intensive care unit; LVEF, left
ventricular ejection fraction; KCCQ, Kansas City Cardiomyopathy Questionnaire
* = statistically significant
**LVEF @ 1 month available for 130 patients (86 GA, 44 CS)
***KCCQ @ 1 month available for 126 patients (83 G, 43 CS)
https://doi.org/10.1371/journal.pone.0173777.t006
Conscious sedation vs general anesthesia in TAVR
PLOS ONE | https://doi.org/10.1371/journal.pone.0173777 April 5, 2017 9 / 12
Limitations
This was a single-center, retrospective review of prospectively maintained databases and, as
such, has certain limitations. Given the novelty of TAVR as a procedure, our study was limited
Table 7. Clinical outcomes, excluding Sapien 1 valves and transapical approach.
Outcomes Total, n = 109 General, n = 60 Sedation, n = 49 P-value
Mortality 0 (0%) 0 (0%) 0 (0%)
1+ Major Adverse Event 36 (33%) 20 (33%) 16 (33%) 0.94
MI 0 (0%) 0 (0%) 0 (0%) NA
Cardiac arrest 0 (0%) 0 (0%) 0 (0%) NA
Major Vasc Event 1 (1%) 0 (0%) 1 (2%) 0.32
Ischemic Stroke 2 (2%) 0 (0%) 2 (4%) 0.16
TIA 1 (1%) 0 (0%) 1 (2%) 0.32
New Dialysis 2 (2%) 2 (3%) 0 (0%) 0.16
GI Bleed 0 (0%) 0 (0%) 0 (0%) NA
GU Bleed 0 (0%) 0 (0%) 0 (0%) NA
Other Bleeding Event 1 (1%) 1 (2%) 0 (0%) 0.32
Annular Dissection 0 (0%) 0 (0%) 0 (0%) NA
Hematoma @ site 2 (2%) 1 (2%) 1 (2%) 0.89
Bleeding @ site 6 (6%) 4 (7%) 2 (4%) 0.55
Unplanned surgery 2 (2%) 2 (3%) 0 (0%) 0.16
Req Pacemaker 18 (17%) 10 (17%) 8 (16%) 0.96
New onset afib 11 (10%) 8 (13%) 3 (6%) 0.20
ICU Hours 47 ± 44 61 ± 48 30 ± 31 <0.001*
Length of Stay (days) 7.1 ± 8.0 8.8 ± 9.8 4.9 ± 4.0 0.006*
30-day readmit 20 (18%) 12 (20%) 8 (16%) 0.62
LVEF @ 1 month** 59 ±12 59 ± 13 57 ± 12 0.96
Change from preop +5 ± 10 +6 ± 10 +3 ± 10 0.26
KCCQ @ 1 month*** 88 ±15 86 ± 18 90 ± 11 0.11
Change from preop +38 ± 26 +37 ± 27 +40 ± 25 0.47
MI, myocardial infarction; TIA, transient ischemic attack; GI, gastrointestinal; GU, genitourinary; Afib, atrial fibrillation; ICU, intensive care unit; LVEF, left
ventricular ejection fraction; KCCQ, Kansas City Cardiomyopathy Questionnaire
* = statistically significant
**30 day LVEF available for 102 patients (58 GA, 44 CS)
***30 day KCCQ scores available for 98 patients (55 GA, 43 CS)
https://doi.org/10.1371/journal.pone.0173777.t007
Table 8. Conscious sedation cost outcomes, matched patients excluding Sapien 1 valves.
Cost Category % of GA Control Cost P-value
Total Direct Cost 73.8% <0.001*
ICU Direct Cost 47.0% <0.001*
Anesthesia Direct Cost 57.8% <0.001*
OR Recovery Direct Cost 44.7% <0.001*
Pharmacy Direct Cost 45.8% 0.001*
Room Direct Cost 46.7% <0.001*
ICU, intensive care unit; OR, operating room
* = statistically significant
https://doi.org/10.1371/journal.pone.0173777.t008
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to a four-year span and relatively small sample size. Additionally, as stated previously, our
institution prohibits publication of actual cost data, requiring that we publish only percent
change. Finally, as this study encompassed only a four-year span and found a significant differ-
ence in cost outcomes, we did not account for inflation.
Conclusion
Conscious sedation is a safe and viable anesthetic option in patients undergoing transfemoral
transcatheter aortic valve replacement. In addition to shorter hospital stays, there is a signifi-
cant reduction in nearly all cost categories with the use of conscious sedation. Whenever possi-
ble, eligible patients undergoing TAVR procedures should preferentially receive conscious
sedation in lieu of general anesthesia.
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